EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study

Chen Huang, Lichen Jin, Yizhang Sun, Menglin Wu, Xuefeng Zhang, Xiaofeng Xu, Xuefeng He, Feng Qiu, Ximing Wang, Lingchuan Guo, Renpeng Huang, Jihui Li und 5 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8610-8620

DOI: 10.1007/s00259-026-08181-x ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 15.09.2026. Verfasst von Chen Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Magnetic Resonance Imaging, Image-Guided Biopsy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The First Affiliated Hospital of Soochow University Clinical Diagnosis and Treatment Technology Innovation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Multiparametric MRI (mpMRI)-ultrasound (US) fusion biopsy misses 8%-20% of clinically significant prostate cancer (csPCa), leaving a detection gap that prostate-specific membrane antigen (PSMA) PET/CT may help close. Whether incorporating PSMA into an MRI-US fusion platform improves csPCa detection has not been evaluated in a prospective paired design. We compared tri-modal PSMA PET/CT-MRI-US fusion biopsy with MRI-US fusion biopsy and systematic biopsy.

Methods

In this prospective, single-center, and paired diagnostic accuracy study (STARD 2015; ChiCTR2400089436), 308 biopsy-naive men underwent tri-modal fusion biopsy, MRI-US fusion biopsy, and systematic biopsy in a single session. The primary endpoint was the absolute difference in patient-level csPCa detection (International Society of Urological Pathology grade group ≥ 2) between tri-modal and MRI-US fusion biopsies.

Results

Tri-modal fusion detected 4.9% more csPCa than MRI-US fusion biopsy (95% confidence interval 2.4%-7.3%; P < 0.001; number needed to biopsy 20.5). The most significant gains were observed for PSMA-positive lesions < 10 mm (8.3%) and Prostate Imaging Reporting and Data System (PI-RADS) 4 lesions (5.8%), and this benefit persisted in multivariate generalized estimating equation models. The PSMA imaging-based risk score (area under the curve, 0.933) showed higher discrimination than the PRIMARY and molecular imaging PSMA scores. In a retrospective simulation using the test set, a risk-guided approach would have avoided approximately 42% of biopsies while missing 2.3% of csPCa. Limitations include the single-center design and the small test set.

Conclusion

Tri-modal fusion was superior to MRI-US fusion biopsy in detecting csPCa, particularly in small PSMA-positive and PI-RADS 4 lesions. A PSMA-derived risk score enabled effective stratification, and in the test set, a simulated risk-guided approach showed potential for biopsy reduction. These findings require multicenter validation before clinical adoption.

Trial registration

ChiCTR2400089436 (Chinese Clinical Trial Registry, http://www.chictr.org.cn/ , registered 2024-09-09).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyMagnetic Resonance ImagingImage-Guided BiopsyGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleProspective StudiesMiddle AgedAgedUltrasonographyClinical Relevance

Stichwörter der Autor:innen

Clinically significant prostate cancerFusion biopsyMultimodal imagingPSMA PET/CTProstate biopsyRisk score

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China.
  • School of Computer Science and Technology, Nanjing Tech University, Nanjing, 211816, China.
  • Carbon Medical Device Ltd, Shenzhen, China.
  • Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China.

Förderung

  • The First Affiliated Hospital of Soochow University Clinical Diagnosis and Treatment Technology Innovation Project

Zitieren

APA

Huang, C., Jin, L., Sun, Y., Wu, M., Zhang, X., Xu, X., He, X., Qiu, F., Wang, X., Guo, L., Huang, R., Li, J., Deng, S., Lin, Y., Wei, X., Zhang, B., & Huang, Y. (2026). Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8610-8620. https://doi.org/10.1007/s00259-026-08181-x

Vancouver

Huang C, Jin L, Sun Y, Wu M, Zhang X, Xu X, et al. Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8610-8620. doi:10.1007/s00259-026-08181-x

BibTeX
@article{Huang2026,
  author = {Huang, Chen and Jin, Lichen and Sun, Yizhang and Wu, Menglin and Zhang, Xuefeng and Xu, Xiaofeng and He, Xuefeng and Qiu, Feng and Wang, Ximing and Guo, Lingchuan and Huang, Renpeng and Li, Jihui and Deng, Shengming and Lin, Yuxin and Wei, Xuedong and Zhang, Bin and Huang, Yuhua},
  title = {Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8610--8620},
  doi = {10.1007/s00259-026-08181-x}
}
Kostenlos starten →